Greetings Friends!

Happy Thanksgiving! While turkey day is just around the corner for those of us in the U.S., that doesn't mean we are all on holiday. One of the world's premiere hematologic conferences is being held in early December and attendees are hard at work finalizing their presentations. Keep reading for an up-to-the-minute look at some of the latest discoveries to be unveiled at the Annual Meeting of the American Society of Hematology. Also, find out how you can show your generosity and support CLL Global this holiday season.

ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

Research Update

The 57th Annual Meeting of the American Society of Hematology (ASH) will be held December 5 - 8, 2015, in Orlando, Florida. The Annual Meeting is the world's premiere event in malignant and non-malignant hematology, bringing together thousands of professionals from around the globe to discuss the hottest topics in hematology research and treatment.

Results from several late-breaking abstracts that highlight novel, high-impact studies will be presented at this year's meeting. Two of these abstracts are specific to CLL.

In the first, Dr. Stephan Stilgenbauer from the University of Ulm in Ulm, Germany, presents results from a phase 2, multi-center study evaluating Venetoclax (ABT-199) in patients with relapsed/refractory (R/R) CLL with 17p deletion.
Results show that Venetoclax monotherapy achieved a high response rate (> 73%) and sustained remissions, including complete remission and undetectable disease. These results represent a depth of response not previously reported for this ultra-high risk population. The full abstract can be found here.

Another late-breaking study led by Dr. Andrew Zelenetz from Memorial Sloan Kettering Cancer Center in New York, NY, also examined treatment of patients with R/R CLL, as well as untreated patients where a 17p or p53 mutation had been identified but who were unsuitable for chemo-immunotherapy. Results of a phase III study evaluating the efficacy of Bendamustine and Rituximab (BR), a standard treatment for R/R CLL patients, versus BR plus Idelalisib, a PI3k delta inhibitor, are described. The study concludes that Idelalisib in combination with BR is superior to BR alone, reducing the risk of progressive disease and increasing overall survival in patients with high-risk features. The full abstract can be found here.

Look for our December issue where we will review highlights from the meeting, keeping you up to date on the latest CLL research and clinical trial findings.

GIVE BACK THIS HOLIDAY SEASON

Sunday, November 29 is Goodshop Sunday

Tired of crowded shops and traffic? Want to get great deals online and support your favorite charity at the same time? Check out the deals at goodshop. All you have to do is search for your favorite charity, like CLL Global, sign up, and start shopping at thousands of your favorite retailers. A portion of each purchase will be donated to the charity of your choice.

Monday, November 30 is Cyber Monday

Planning to knock out a little holiday shopping and catch a few deals this Cyber Monday? Help support CLL Global while you whittle down that gift list. Shopping at Amazon? Just go to the amazonSmile website, select CLL Global as the charitable organization you would like to support, and for eligible purchases the AmazonSmile Foundation will donate 0.5% of the purchase price to CLL Global.
December 1 is Giving Tuesday

During this holiday season, while we reflect on those things in our lives for which we are grateful, please consider sharing that gratitude. On Tuesday, December 1, 2015, the global community comes together to celebrate generosity and the power of making a difference. Be a part of that movement and help brighten the lives and future for patients with CLL across the globe. You can make a donation to CLL Global Research Foundation here.

THANK YOU FOR SUPPORTING US!

CLL Global would like to extend a heartfelt thank you to all of our friends and family who have supported us throughout the year. Thanksgiving provides us the perfect opportunity to take a break from our typically hectic schedules and remember how fortunate we are to have shared this holiday with so many wonderful people throughout the years. While those seated at the dinner table may change over time, and the turkey may be tastier some years more than others, every gathering is a blessing for which we are grateful. Happy Thanksgiving.

Sincerely,

CLL Global Research Foundation